OakChart

Lexaria Bioscience Corp

LEXXHealthcare·Biotechnology·Canada·Nano·NASD·Nov 11 • 1:26 PM ET

4.67-0.01 (-0.21%)
2026-11-11 19:38 CET
Market cap
9.86 USD m
Revenue, TTM
0.19 USD m
Net income, TTM
-7.73 USD m
Free cash flow, TTM
-7.47 USD m
EPS diluted, TTM
-5.28
P/E
-
Compare

Price

LEXX against its 20, 50 and 200-day averages
2050200miss
5.0010.0015.00253K506KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LEXXclose 4.6720-day 3.5550-day 4.16200-day 8.664.6752w low

78.4% under the 52-week high of 21.60 on 12 Dec 2025. 52-week low 2.43 on 14 Oct 2026. Last 15 sessions, 90.8% high to low

Profile

LEXX
52-week range, 12% of the way up
2.4321.60

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the IP licensing segment which generates revenue from customers by licensing its proprietary DehydraTECH technology. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Employees7
IPOOct 10, 2006
Beta0.53
ATR, 14d0.47
Rel volume0.09
Short float10.66%
Insider own2.96%
Inst own4.94%

Snapshot

6 groups

Valuation

Index-
Market Cap9.84M
Enterprise Value5.92M
Income-7.73M
Sales0.19M
Book/sh2.87
Cash/sh1.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees7
IPOOct 10, 2006

Ratios

P/E-
Forward P/E-
PEG-
P/S51.78
P/B1.63
P/C2.72
P/FCF-
EV/EBITDA-
EV/Sales31.15
Quick Ratio10.60
Current Ratio10.60
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-5.28
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y18.80% 14.16%
Sales past 3/5Y40.34% 17.53%
EPS Y/Y TTM46.85%
Sales Y/Y TTM-68.50%
EPS Q/Q61.24%
Sales Q/Q-100.00%
EarningsJul 17
EPS/Sales Surpr.-33.33% -

Ownership

Insider Own2.96%
Insider Trans0.00%
Inst Own4.94%
Inst Trans0.25%
ROA-134.21%
ROE-150.28%
ROIC-161.36%
Gross Margin48.98%
Oper. Margin-3862.94%
Profit Margin-3985.58%
SMA2031.57%
SMA5012.30%
SMA200-46.05%
Trades-

Technical

Shs Outstand2.11M
Shs Float2.04M
Short Float10.66%
Short Ratio2.97
Short Interest0.22M
52W High21.60 -78.38%
52W Low2.43 92.18%
Volatility9.44% 13.84%
ATR (14)0.47
RSI (14)63.50
Beta0.53
Rel Volume0.09
Avg Volume73.29K
Volume4,464

Performance

Perf Week14.74%
Perf Month66.79%
Perf Quarter-42.35%
Perf Half Y-48.32%
Perf YTD-49.54%
Perf Year-72.20%
Perf 3Y-77.92%
Perf 5Y-95.22%
Perf 10Y-95.93%
Recom1.00
Target Price82.50
Prev Close4.68
Price4.67
Change %-0.21%

Peers

Mkt cap
TickerCompanyMkt cap
ORMPOramed Pharmaceuticals Inc169.09M
RANIRani Therapeutics Holdings Inc78.16M
ENTXEntera Bio Ltd558.99M
LPCNLipocine Inc17.72M
MTVAMetaVia Inc9.52M
GUTSFractyl Health Inc11.60M
ARTLArtelo Biosciences Inc1.19M
NTRBNutriband Inc72.88M
IGCIGC Pharma Inc22.69M
ALTAltimmune Inc376.39M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH (ACCESSWIRE)
  • Lexaria Celebrates its 70th Patent Award (ACCESSWIRE)
  • Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule (ACCESSWIRE) +6.42%
  • Lexaria Announces Results from Animal Study GLP-1-A26-1 (ACCESSWIRE) +6.03%
  • GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications (ACCESSWIRE) +16.97%
  • Lexaria Updates Financial Position (ACCESSWIRE) +6.30%
  • Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds (ACCESSWIRE) -29.56% -38.64%
  • Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds (ACCESSWIRE) -33.78%
  • Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference (ACCESSWIRE) +14.85%
  • Lexaria Receives USD$2.6 Million Tax Rebate Payment (ACCESSWIRE) +10.59%
  • DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 (ACCESSWIRE)
  • Lexaria Enters a Material Transfer Agreement With PegBio (ACCESSWIRE) +32.35%
  • Lexaria Announces Effective Date for Reverse Stock Split (ACCESSWIRE) -25.23%
  • Lexaria Updates Business Development (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-07-17-1.200-0.900-1.2000.000.001
2026Q22026-04-14-1.050-1.050-0.8900.000.001
2026Q12026-01-21-1.050-1.950-1.1190.000.101
2025Q42025-10-29-2.100-2.400-2.0670.200.142
2025Q32025-07-18-3.150-2.175-3.1060.170.142
2025Q22025-04-15-2.250-2.450-2.3240.170.153
2025Q12025-01-15-2.400-1.800-2.4330.180.101
2024Q42024-10-30-2.100-1.800-2.0730.090.201
2024Q32024-07-19-1.950-1.950-1.9290.000.113
2024Q22024-04-09-0.900-1.500-0.9050.15-1
2024Q12024-01-17-1.950-1.650-1.9540.15-1
2023Q42023-11-01-2.250-2.550-2.2500.000.181
2023Q32023-07-14-5.550-3.750-5.5230.090.011
2023Q22023-04-19-3.300--3.2720.04--
2023Q12023-01-18-4.500--4.4260.10--
2022Q32022-11-28-6.150-4.200-6.0060.100.121

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY---14.3150.06-
2018FY-40.500-45.000-41.8460.430.45
2021FY-14.250-14.625-13.7550.720.93
2022FY-18.150-18.150-18.5280.300.34
2023FY-15.150-15.450-15.1150.230.41
2024FY-7.050-6.600-7.0200.480.50
2025FY-9.900-10.200-9.7500.700.67
2026FY--4.050--0.02
2027FY--4.650--1.40
2028FY--4.200--1.59
2029FY-20.100--70.19

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-07-171000.000.000.00
2026Q4S2026-04-141000.000.000.00
2026Q4S2026-04-041000.000.000.00
2026Q4S2026-02-092000.050.000.10
2026Q4S2026-01-211000.100.100.10
2026Q4S2025-11-111000.100.100.10
2026Q4S2025-11-101000.100.100.10
2026Q4S2025-11-091000.100.100.10
2026Q4S2025-11-081000.100.100.10
2026Q4S2025-11-071000.100.100.10
2026Q4S2025-11-061000.100.100.10
2026Q4S2025-11-051000.100.100.10
2026Q4S2025-11-041000.100.100.10
2026Q4S2025-11-031000.100.100.10

Estimate history

EPS, annual-14.315-41.846-23.715-21.276-13.755-18.528-15.115-7.02-9.919-5.2806
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.929-2.073-2.433-2.324-3.106-2.067-1.119-0.89-1.204
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.0640.4330.2230.3150.7230.2550.2260.4640.7060.19
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0840.0840.1840.1740.1740.17400.020
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.1510.1680.1750.20.3820.3970.5391.0541.3041.652
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.0541.0541.1641.1631.2971.3041.4821.6591.652
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.190.710.460.230.260.720.310.220.43
Cost of Goods Sold Incl. D&A0.100.120.080.170.210.180.250.420.03
Gross Profit0.100.590.380.050.050.550.07-0.190.41
Selling, General and Administrative Excl. Other7.5912.226.086.596.556.074.203.947.01
Research and Development4.008.242.363.671.841.260.390.560.49
Other Operating Expense0.000.000.000.000.000.000.000.010.01
Operating Income-7.49-11.63-5.70-6.53-6.50-5.52-4.13-4.14-6.61
Interest Expense0.000.000.000.000.00----
Unusual Expense0.250.280.130.220.880.170.020.02-
Net Income Before Taxes-7.74-11.91-5.81-6.71-7.38-4.16-4.15-4.16-6.61
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-7.74-11.91-5.81-6.71-7.38-4.16-4.15-4.16-6.61
Net Income From Continuing Operations-7.73-11.90-5.80-6.66-7.27-4.01-4.00-4.10-6.60
Net Income-7.73-11.90-5.80-6.66-7.27-4.03-3.93-4.10-6.60
EPS (Recurring)-4.57-9.75-6.91-14.76-16.95-13.36-21.20-23.65-41.85
EPS (Basic, Before Extraordinaries)-5.28-9.92-7.02-15.12-18.53-13.76-21.28-23.71-41.85
EPS (Diluted)-5.28-9.92-7.02-15.12-18.53-13.76-21.28-23.71-41.85
EBITDA-7.40-11.52-5.62-6.39-6.35-5.37-3.98-4.08-6.61
Non-Operating Income (Expense)0.010.000.010.040.001.520.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.330.860.490.170.750.411.140.632.60
Price To Sales Ratio76.9822.44104.2930.7068.2137.7991.42241.12335.73
Gross Margin48.9883.2082.5623.8618.2975.7422.02-87.1693.66
Operating Margin-3,862.94-1,647.97-1,226.70-2,888.50-2,545.39-763.84-1,311.63-1,860.64-1,526.28
Net Margin-3,985.58-1,686.00-1,248.25-2,946.36-2,846.28-557.19-1,249.71-1,841.53-1,522.97
Shares Outstanding1.651.301.050.540.400.380.200.180.17
Market Capitalization9.869.8661.828.5017.6135.6231.1454.12154.84

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.020.000.170.170.170.180.08
Cost of Goods Sold Incl. D&A0.030.030.020.020.020.020.040.02
Gross Profit-0.03-0.01-0.020.150.160.160.150.07
Selling, General and Administrative Excl. Other1.971.451.552.633.912.912.772.27
Research and Development0.970.480.671.882.721.691.950.97
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.99-1.45-1.57-2.47-3.75-2.75-2.62-2.20
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.020.230.04-0.030.02-0.01
Net Income Before Taxes-1.99-1.45-1.60-2.70-3.79-2.72-2.71-2.19
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.99-1.45-1.60-2.70-3.79-2.72-2.71-2.19
Net Income From Continuing Operations-1.99-1.45-1.60-2.70-3.79-2.71-2.70-2.18
Net Income-1.99-1.45-1.60-2.70-3.79-2.71-2.70-2.18
EPS (Recurring)-1.20-0.89-1.11-1.95-3.08-2.34-2.42-2.08
EPS (Basic, Before Extraordinaries)-1.20-0.89-1.12-2.07-3.11-2.32-2.43-2.07
EPS (Diluted)-1.20-0.89-1.12-2.07-3.11-2.32-2.43-2.07
EBITDA-1.97-1.43-1.55-2.45-3.73-2.73-2.59-2.19
Non-Operating Income (Expense)0.000.000.000.000.000.00-0.070.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.070.070.060.120.470.170.100.10
Price To Sales Ratio76.9846.4344.6424.3930.3048.9569.77133.15
Gross Margin--32.84-87.7091.1489.7680.4780.51
Operating Margin--7,259.51--1,422.28-2,155.41-1,581.04-1,424.04-2,622.70
Net Margin--7,249.89--1,549.33-2,177.64-1,559.32-1,470.02-2,600.94
Shares Outstanding1.651.661.481.301.301.161.161.05
Market Capitalization9.8615.5421.3217.1317.8025.6532.8961.82

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1.976.561.486.1611.751.311.351.742.53
Short Term Receivables0.370.150.180.200.340.310.270.270.05
Inventories0.000.000.000.040.030.120.130.090.07
Other Current Assets1.131.190.550.580.320.180.070.190.15
Total Current Assets3.477.902.206.9812.441.931.822.282.80
Net Property, Plant & Equipment0.330.390.420.370.460.610.590.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable0.060.06-------
Intangible Assets0.310.520.460.490.360.290.270.150.06
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets4.188.873.087.8313.272.832.682.432.86
Short Term Debt Incl. Current Port. of LT Debt0.030.030.030.040.050.040.000.010.04
Accounts Payable0.570.380.230.060.050.050.030.040.03
Income Tax Payable---0.00-----
Other Current Liabilities0.890.690.010.090.050.140.150.000.02
Total Current Liabilities1.491.100.270.190.150.230.180.040.09
Long Term Debt0.080.110.140.010.050.120.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities1.571.210.400.200.200.350.180.040.09
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity2.998.043.047.9513.272.532.382.393.01
Total Shareholders Equity2.998.043.047.9513.272.532.382.393.01
Accumulated Minority Interest-0.39-0.38-0.36-0.32-0.20-0.040.110.00-0.24
Total Equity2.607.662.687.6313.062.482.492.392.77
Total Liabilities & Stockholders Equity4.188.873.087.8313.272.832.682.432.86
Book Value Per Share2.297.625.6420.0434.7512.6213.6114.2319.90
Tangible Book Value Per Share2.067.134.7918.8033.7911.1612.1013.3519.49
Full-Time Employees775764---
Price to Book Ratio1.636.111.932.222.6912.3317.0264.847.91
Return on Assets-182.50-96.98-122.09-68.90-49.77-145.30-160.54-249.39-109.10
Return on Equity-215.88-104.60-121.26-68.53-50.73-162.92-171.84-244.65-114.25
Return on Invested Capital-387.86-71.15-209.57-91.37-30.24-148.72-172.02-276.31-62.18
Quick Ratio2.327.188.2235.7680.998.019.1750.3429.54
Current Ratio2.327.188.2235.9681.188.539.8652.3430.27

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-7.74-11.91-5.81-6.71-7.38-4.19-4.08-4.16-6.61
Depreciation0.130.120.080.150.140.150.150.060.00
Other Funds (Non Cash)0.601.150.670.542.71-0.011.511.014.46
Funds from Operations-7.01-10.65-5.07-6.02-4.53-4.05-2.42-3.09-2.15
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.410.200.110.14-0.350.06-0.190.04-0.34
Cash from Operating Activities-7.43-10.45-4.96-5.88-4.88-3.99-2.62-3.05-2.48
Capital Expenditures-0.10-0.10-0.19-0.17-0.18-0.08-0.03-0.77-0.09
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-0.07
Sale of Fixed Assets and Businesses0.000.000.000.000.000.270.000.000.00
Purchase or Sale of Investments-0.14-0.140.000.000.000.000.010.000.00
Purchase of Investments-0.14-0.140.000.000.000.000.000.00-
Sale Or Maturity of Investments0.000.000.000.000.000.000.010.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-0.24-0.24-0.19-0.17-0.180.19-0.03-0.77-0.16
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock6.526.0510.321.590.0013.492.672.331.87
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.526.0510.321.590.0013.492.672.331.87
Proceedsfrom Stock Options6.526.054.211.590.009.472.672.331.87
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.020.030.04-0.03
Change in Long Term Debt0.000.000.000.000.00-0.020.030.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.030.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.020.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.04-0.04-0.041.000.00
Other Financing Activities Uses0.000.000.000.00-0.04-0.04-0.040.000.00
Cash from Financing Activities6.526.0510.321.59-0.0413.422.653.371.83
Exchange Rate Effect0.03-0.05-0.02------
Net Change in Cash-1.12-4.705.15-4.46-5.109.620.01-0.44-0.81
Free Cash Flow-7.47-10.48-5.00-5.91-4.93-3.99-2.62-3.69-2.48
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments3.625.274.421.974.636.54
Short Term Receivables0.050.040.090.370.360.33
Inventories0.000.000.000.000.000.00
Other Current Assets0.400.460.851.130.820.85
Total Current Assets4.065.775.363.475.817.72
Net Property, Plant & Equipment0.310.330.320.330.350.38
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.340.320.310.310.520.51
Other Assets0.000.000.000.000.000.00
Total Assets4.786.496.054.186.748.68
Short Term Debt Incl. Current Port. of LT Debt0.030.030.030.030.030.03
Accounts Payable0.100.041.180.570.601.28
Other Current Liabilities0.250.150.250.890.860.51
Total Current Liabilities0.380.211.461.491.491.82
Long Term Debt0.050.060.070.080.090.09
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.440.281.531.571.571.92
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.746.604.912.995.557.14
Total Shareholders Equity4.746.604.912.995.557.14
Accumulated Minority Interest-0.39-0.39-0.39-0.39-0.39-0.38
Total Equity4.346.214.522.605.176.76
Total Liabilities & Stockholders Equity4.786.496.054.186.748.68
Book Value Per Share2.873.983.322.294.286.14
Tangible Book Value Per Share2.663.793.112.063.885.71
Full-Time Employees---7--
Price to Book Ratio1.633.167.133.092.493.59
Return on Assets-134.21-125.68-136.24-182.50-135.93-124.87
Return on Equity-150.28-138.64-146.97-215.88-145.34-137.33
Return on Invested Capital-41.55-21.76-32.00-87.85-67.20-37.48
Quick Ratio10.6026.883.682.323.904.24
Current Ratio10.6026.883.682.323.904.24

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-1.99-1.45-1.60-2.70-3.79-2.72
Depreciation0.030.030.020.050.030.00
Other Funds (Non Cash)0.090.080.100.330.520.18
Funds from Operations-1.87-1.35-1.47-2.32-3.24-2.54
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.24-0.810.49-0.32-0.341.04
Cash from Operating Activities-1.64-2.16-0.98-2.64-3.58-1.50
Capital Expenditures-0.03-0.06-0.01-0.01-0.02-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-0.000.000.00-0.140.000.00
Purchase of Investments0.000.000.00-0.140.000.00
Sale Or Maturity of Investments-0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.05-0.01-0.16-0.02-0.03
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.003.043.470.001.690.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.003.043.470.001.690.01
Proceedsfrom Stock Options0.003.043.470.001.690.01
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.003.043.470.001.690.01
Exchange Rate Effect0.010.02-0.010.010.04-0.10
Net Change in Cash-1.650.852.48-2.79-1.88-1.61
Free Cash Flow-1.64-2.20-0.98-2.64-3.58-1.50

Revenue breakdown

B2B2024: 6.29K 2025: 9.92K
IP Licensing2024: 457.99K 2025: 696.00K
Canada2024: 464.28K 2025: 705.92K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.66%0.2M2.0M74.86K
2026-10-1512.54%0.3M2.0M69.51K
2026-09-3013.46%0.3M2.0M57.67K
2026-09-158.77%0.2M2.0M47.09K
2026-08-312.23%0.0M1.6M29.68K
2026-08-141.74%0.0M1.6M11.52K
2026-07-311.02%0.0M1.6M7.19K
2026-07-150.68%0.0M1.6M7.92K
2026-06-301.43%0.0M1.6M9.90K
2026-06-151.50%0.0M1.6M10.79K
2026-05-291.46%0.0M1.6M11.76K
2026-05-151.59%0.0M1.6M11.93K
2026-04-301.44%0.0M1.6M12.56K
2026-04-151.59%0.0M1.6M11.35K
2026-03-311.20%0.0M1.6M12.03K
2026-03-131.58%0.0M1.6M41.10K
2026-02-271.63%0.0M1.6M40.82K
2026-02-132.77%0.0M1.6M41.22K
2026-01-302.68%0.0M1.6M41.90K
2026-01-154.49%0.1M1.6M42.22K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-13EFFECTEffectiveness filing by commission orderSEC
2026-10-13424B3SEC
2026-10-02S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-21DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-098-KCurrent report2026-09-07SEC
2026-09-018-KCurrent report2026-08-28SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-108-KCurrent report2026-08-04SEC
2026-07-308-KCurrent report2026-07-29SEC
2026-07-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-05-31SEC
2026-04-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-02-28SEC
2026-03-184Statement of changes in beneficial ownership of securities2026-03-17SEC
2026-02-068-KCurrent report2026-02-04SEC
2026-01-288-KCurrent report2026-01-27SEC
2026-01-28S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-01-14EFFECTEffectiveness filing by commission orderSEC
2026-01-14424B3SEC
2026-01-1425-NSESEC
2026-01-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-11-30SEC
2025-12-29S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2025-12-19DNotice of sales of securities on Form D (Regulation D)SEC
2025-12-168-KCurrent report2025-12-14SEC
2025-12-16424B5SEC
2025-12-10DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-01-27SEC
2025-12-09EFFECTEffectiveness filing by commission orderSEC
2025-12-09424B3SEC
2025-12-08EFFECTEffectiveness filing by commission orderSEC
2025-12-05POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2025-12-05CORRESPSEC
2025-12-05S-1/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Invenomic Capital Management LP1.39%
VANGUARD CAPITAL MANAGEMENT LLC1.20%
GEODE CAPITAL MANAGEMENT, LLC0.79%
CITADEL ADVISORS LLC0.63%
UBS Group AG0.61%
TORONTO DOMINION BANK0.40%
VANGUARD FIDUCIARY TRUST CO0.38%
HRT FINANCIAL LP0.26%
NORTHERN TRUST CORP0.16%
STATE STREET CORP0.16%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.20%
Fidelity Extended Market Index Fund0.52%
Invenomic Fund0.40%
Fidelity Series Total Market Index Fund0.13%
Fidelity Total Market Index Fund0.11%
Fidelity Nasdaq Composite Index Fund0.04%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. LEXX. Cached 15 minutes.

Some panels did not load: ratings, insider.